Marilyn K. Glassberg <br/><br/>
Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis 

<br/><br/><label>Subjects--Topical Terms: </label><br/>Computer science, information & general works